MedTrace Logo

A Trial of HR17031 Injection With Hepatic Insufficiency

NCT05151705 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-12-09

No results posted yet for this study

Summary

This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild and moderate liver impairment and subjects with normal liver function.

Conditions

  • Improved Glycemic Control in Patients With Type 2 Diabetes

Interventions

DRUG

HR17031 injection

Treatment group A:HR17031 injection; 10U/0.024mg

DRUG

HR17031 injection

Treatment group B: HR17031 injection; 10U/0.024mg

DRUG

HR17031 injection

Treatment group C: HR17031 injection; 10U/0.024mg

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-20
Primary Completion
2022-06-15
Completion
2022-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05151705 on ClinicalTrials.gov